Physician profile
John Sokolowicz
NPI 1518067032
$2,083.88
in general payments reported to CMS, 2019-2025
20 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $432 · 2021: $429 · 2022: $177 · 2023: $126 · 2024: $132 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $323.19 | 2019-2024 | Xarelto |
| Biotronik INC. | $269.89 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $233.50 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $195.14 | 2020-2024 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $191.81 | 2019-2024 | Camzyos |
| Amgen INC. | $159.63 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $154.69 | 2025 | Venclose Maven Catheter |
| Novartis Pharmaceuticals Corporation | $133.49 | 2021-2024 | |
| Pfizer INC. | $118.46 | 2019-2024 | |
| Esperion Therapeutics, INC. | $90.58 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $56.04 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $48.89 | 2022-2024 | Optimizer |
| Amarin Pharma, INC. | $30.77 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $20.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.10 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $15.40 | 2024 | Assure Wcd |
| Boston Scientific Corporation | $12.70 | 2023 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sokolowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.